Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.55 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.55 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.55 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | ADH5 | P11766 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27943945 | 0.85 | TBXAS1 (0.58) | TBXAS1LMNAMAPTENPP2MKNK1 | |
| SCHEMBL7275362 | 0.82 | TBXAS1 (0.63) | TBXAS1LMNAMAPTENPP2MKNK1 | |
| SCHEMBL8401615 | 0.81 | ENPP2 (0.54) | TBXAS1LMNAMAPTENPP2MKNK1 | |
| SCHEMBL27613141 | 0.81 | ENPP2 (0.54) | TBXAS1LMNAMAPTENPP2MKNK1 | |
| SCHEMBL21791731 | 0.81 | LMNA (0.62) | TBXAS1LMNAMAPTENPP2MKNK1 | |
| SCHEMBL2532397 | 0.80 | LMNA (0.78) | LMNAMAPTENPP2MKNK1MKNK2 | |
| SCHEMBL19920014 | 0.80 | IDO1 (0.59) | CYP3A4MEN1ALOX15TSHRKMT2A | |
| SCHEMBL25345045 | 0.80 | TBXAS1 (0.57) | TBXAS1LMNAMAPTENPP2MKNK1 | |
| SCHEMBL8288350 | 0.79 | MAPT (0.60) | LMNAMAPTENPP2MKNK1MKNK2 | |
| SCHEMBL209879 | 0.79 | MAPT (0.60) | LMNAMAPTENPP2MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1553949-B1 | PYRIMIDINE-2,4-DIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2007-04-18 | — | — | EP | disclosed |
| US-7160893-B2 | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| EP-1553949-A2 | PYRIMIDINE-2,4-DIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-07-20 | — | — | EP | disclosed |
| US-20040053952-A1 | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors | HICKS JAMES LESTER (US) | 2004-03-18 | — | — | US | disclosed |
| WO-2004014868-A2 | PYRIMIDINE-2,4-DIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053952-A1 | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors | MMP1, MMP9, MMP13 | TBXAS1 199/4885LMNA 3796/4885MAPT 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.